▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #693 by analyst upside · 2026-09-29
GLUE
Monte Rosa Therapeutics, Inc.
Healthcare · Market Cap $999M · P/E 0x
ANALYST PRICE TARGET
+143.4%
implied upside to consensus target
Current Price $11.71
Consensus Target $28.5
Bull Target $37.0
Bear Target $25.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $7.09
52-Week High $25.77
YTD Return -23.5%
FUNDAMENTALS
Market Cap $999M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.75
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $29M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $7.09
52-Week High $25.77
Current Price $11.71
Bear Target $25.0
Bull Target $37.0
● Now $11.71 ● Target $28.5
TRADING DATA
Avg Volume 1.3M
YTD Return -23.5%
Analyst Count 6
Consensus Buy
Upside to Target +143.4%
Last Updated 2026-09-29

ANALYST SUMMARY

Monte Rosa Therapeutics, Inc. (GLUE) is currently trading at $11.71 with a Wall Street consensus price target of $28.5, implying potential upside of 143.4% over the next 12 months. 6 analysts currently cover GLUE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $37.0, while the most cautious has a target of $25.0.

GLUE operates in the Healthcare sector with a market capitalisation of $999M. The stock is down 23.5% year-to-date and is currently trading near the lower end of its 52-week range of $7.09 – $25.77.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

APMD +132.3%
Apnimed, Inc.
$902M · P/E 3.7x · Buy
VOR +113.0%
Vor Biopharma Inc.
$1B · P/E 0.1x · Buy
MGTX +149.8%
MeiraGTx Holdings plc
$1B · P/E 13.5x · Buy
ZVRA +121.2%
Zevra Therapeutics, Inc.
$671M · P/E 12.2x · Buy
COLL +116.5%
Collegium Pharmaceutical, Inc.
$702M · P/E 17.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GLUE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush reit
Outperform → Outperform 2026-09-09 Building track record
Guggenheim reit
Buy → Buy 2026-08-25 62% win rate (8 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-08-07 43% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-08-07 62% win rate (8 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-08-07 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-08-03 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-06-30 62% win rate (8 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-05-11 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
52
out of 100
Coverage depth
15/30
Consensus clarity
10/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →